Stock APPAD HERON THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Heron Therapeutics Inc OTC Bulletin Board

Equities

APPAD

US4277461020

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product under the Proposed 2025 Non-Opioid Policy for Pain Relief under the OPPS and the ASC Payment System
AQ
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
PR
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
PR
Heron Therapeutics : Investor Day Presentation
PU
Heron Therapeutics: Q1 Earnings Snapshot
AQ
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
PR
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
PR
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
PR
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
PR
Heron Therapeutics : Q4 2023 Earnings Call Presentation
PU
Heron Therapeutics : Q4 2023 Earnings Call Presentation
PU
Heron Therapeutics: Q4 Earnings Snapshot
AQ
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
PR
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
PR
Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
AQ
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
PR
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
AQ
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
PR
Heron Therapeutics: Q3 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRTX Stock
  4. APPAD Stock
  5. News Heron Therapeutics Inc
  6. Press Releases